Clinical Trials Browser

Recurrence × elacestrant × 90 days × Clear all

NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms